BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1620 related articles for article (PubMed ID: 11081374)

  • 1. [Basic principles of hormone replacement therapy in the postmenopause].
    Dören M
    Ther Umsch; 2000 Oct; 57(10):628-34. PubMed ID: 11081374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effects on bone mineral density of tibolone, transdermal estrogen and oral estrogen/progestogen therapy in postmenopausal women.
    Prelevic GM; Bartram C; Wood J; Okolo S; Ginsburg J
    Gynecol Endocrinol; 1996 Dec; 10(6):413-20. PubMed ID: 9032569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone.
    Lippuner K; Haenggi W; Birkhaeuser MH; Casez JP; Jaeger P
    J Bone Miner Res; 1997 May; 12(5):806-12. PubMed ID: 9144347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Postmenopausal estrogen therapy: pharmacological treatment or replacement of the lacking hormone?].
    Lippert TH; Seeger H; Mueck AO
    Dtsch Med Wochenschr; 1999 Oct; 124(42):1245-8. PubMed ID: 10572534
    [No Abstract]   [Full Text] [Related]  

  • 5. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
    Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
    Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
    Rozenberg S; Ylikorkala O; Arrenbrecht S
    Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women.
    Castelo-Branco C; Vicente JJ; Figueras F; Sanjuan A; Martínez de Osaba MJ; Casals E; Pons F; Balasch J; Vanrell JA
    Maturitas; 2000 Feb; 34(2):161-8. PubMed ID: 10714911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen-progestogen replacement therapy in postmenopausal women--is 1 mg estradiolvalerate sufficient to maintain axial trabecular bone density?
    Dören M; Schneider HP
    Int J Clin Pharmacol Ther; 1994 May; 32(5):254-8. PubMed ID: 7921520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
    Parish SJ; Gillespie JA
    Postgrad Med; 2017 Apr; 129(3):340-351. PubMed ID: 28132583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
    Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
    Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium.
    Johannisson E; Holinka CF; Arrenbrecht S
    Int J Fertil Womens Med; 1997; 42 Suppl 2():388-98. PubMed ID: 9397386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous versus cyclical transdermal estrogen replacement therapy in postmenopausal women: influence on climacteric symptoms, body weight and bleeding pattern.
    Lübbert H; Nauert C
    Maturitas; 1997 Dec; 28(2):117-25. PubMed ID: 9522319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing the dose of hormone replacement therapy.
    Rice VM
    Int J Fertil Womens Med; 2002; 47(5):205-10. PubMed ID: 12469707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women.
    Ziaei S; Moghasemi M; Faghihzadeh S
    Climacteric; 2010 Apr; 13(2):147-56. PubMed ID: 19731119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Indications for hormone replacement therapy].
    Birkhäuser MH
    Ther Umsch; 2000 Oct; 57(10):635-42. PubMed ID: 11081375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative cardiovascular effects of different progestins in menopause.
    Rosano GM; Fini M
    Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women.
    Nugent AG; Leung KC; Sullivan D; Reutens AT; Ho KK
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):690-8. PubMed ID: 14974909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferential prescribing of tibolone and combined estrogen plus progestogen therapy in postmenopausal women.
    Velthuis-Te Wierik EJ; Hendricks PT; Martinez C
    Menopause; 2007; 14(3 Pt 1):518-27. PubMed ID: 17224856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding.
    Lethaby A; Suckling J; Barlow D; Farquhar CM; Jepson RG; Roberts H
    Cochrane Database Syst Rev; 2004; (3):CD000402. PubMed ID: 15266429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 81.